Sonoma Pharmaceuticals (SNOA) Change in Accured Expenses (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Change in Accured Expenses of -$276000.0 for Q1 2026, down 241.54% year-over-year from $195000.0 in Q1 2025, and down 545.16% quarter-over-quarter from $62000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$276000.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 241.54% year-over-year to -$276000.0; the TTM figure through Mar 2026 stood at -$100000.0 (down 151.55% YoY), while the FY2026 annual figure was -$100000.0, down 151.55% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$276000.0, down from $62000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $598000.0 in Q3 2025, with the low at -$484000.0 in Q2 2025.
- The 5-year median for Change in Accured Expenses is $53000.0 (2024), against an average of $57941.2.
- Peak annual rise in Change in Accured Expenses reached 1200.0% in 2025, while the deepest fall reached 1013.21% in 2025.
- Sonoma Pharmaceuticals' Change in Accured Expenses stood at $390000.0 in 2022, then sank by 184.62% to -$330000.0 in 2023, then jumped by 69.7% to -$100000.0 in 2024, then soared by 162.0% to $62000.0 in 2025, then plunged by 545.16% to -$276000.0 in 2026.
- Business Quant data shows SNOA's Change in Accured Expenses at -$276000.0 in Q1 2026, $62000.0 in Q4 2025, and $598000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.12 Mn | -222,819.83 | 2.58 Mn | 391,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 391,000.00 |
| Jun 30, 2026 | 391,000.00 |
| Mar 31, 2026 | -276,000.00 |
| Mar 31, 2026 | -276,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Jun 30, 2025 | -484,000.00 |
| Jun 30, 2025 | -484,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Dec 31, 2024 | -100,000.00 |
| Dec 31, 2024 | -100,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |